MODERN ASPECTS OF MIGRAINE MANAGEMENT

Authors

  • Akhmadov Jakhongir Akmal ugli Asia International University, Bukhara, Uzbekistan

DOI:

https://doi.org/10.55640/

Keywords:

migraine, CGRP, gepants, triptans, monoclonal antibodies, neuromodulation, migraine therapy

Abstract

Migraine is a common and disabling neurological disorder characterized by recurrent attacks of moderate to severe headache often accompanied by nausea, vomiting, photophobia, and phonophobia. It affects approximately 15% of the global population and represents one of the leading causes of disability worldwide. Modern approaches to migraine management have evolved significantly with the advancement of knowledge about migraine pathophysiology, particularly the role of the trigeminovascular system and calcitonin gene‑related peptide (CGRP). Contemporary treatment strategies focus on both acute attack relief and long‑term prevention using pharmacological and non‑pharmacological methods. Traditional therapies such as non‑steroidal anti‑inflammatory drugs (NSAIDs), triptans, beta‑blockers, antidepressants, and antiepileptic medications remain widely used. However, the development of targeted therapies including CGRP monoclonal antibodies, gepants, and ditans has significantly transformed migraine management. Additionally, neuromodulation techniques and lifestyle‑based interventions are gaining increasing importance in modern clinical practice. This article reviews current concepts in migraine pathophysiology, diagnostic criteria, and modern therapeutic approaches including pharmacological treatments, preventive strategies, and emerging innovative therapies.

Downloads

Download data is not yet available.

References

1.American Headache Society. Calcitonin Gene-Related Peptide-Targeting Therapies for Prevention of Migraine: Position Statement Update. Headache: The Journal of Head and Face Pain. 2024.

2.American Headache Society. Consensus Guidance on CGRP-Targeting Therapies in Migraine Prevention. 2024 update.

3.American College of Physicians. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: Clinical Guideline. Annals of Internal Medicine. 2025.

4.International Headache Society. International Classification of Headache Disorders (ICHD-3). Cephalalgia.

5.American Academy of Neurology. Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults. Neurology.

6.Peter J. Goadsby, Messoud Ashina, et al. Pathophysiology of Migraine and Therapeutic Targets. Physiological Reviews.

7.David W. Dodick. CGRP Monoclonal Antibodies for Migraine Prevention. New England Journal of Medicine.

8.Stephen D. Silberstein. Preventive Migraine Therapy. Continuum: Lifelong Learning in Neurology.

9.World Health Organization. Headache Disorders: Global Burden of Disease Report

Downloads

Published

2026-03-21

How to Cite

MODERN ASPECTS OF MIGRAINE MANAGEMENT. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(03), 1654-1658. https://doi.org/10.55640/

Similar Articles

11-20 of 248

You may also start an advanced similarity search for this article.